e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country
Dumitru Chesov, Jan Heyckendorf, Sofia Alexandru, Ana Donica, Elena Chesov, Maja Reimann, Valeriu Crudu, Victor Botnaru, Christoph Lange
Source:
Eur Respir J, 57 (6) 2002544; 10.1183/13993003.02544-2020
Journal Issue:
June
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Dumitru Chesov, Jan Heyckendorf, Sofia Alexandru, Ana Donica, Elena Chesov, Maja Reimann, Valeriu Crudu, Victor Botnaru, Christoph Lange. Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country. Eur Respir J, 57 (6) 2002544; 10.1183/13993003.02544-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings
Source: Eur Respir J, 59 (1) 2004345; 10.1183/13993003.04345-2020
Year: 2022
Evaluation of treatment outcomes for multidrug-resistant tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 312s
Year: 2001
Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB)
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007
Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal
Source: Eur Respir J 2013; 42: 1747-1749
Year: 2013
Treatment outcomes for multidrug-resistant tuberculosis (MDR-TB) patients in Africa
Source: Annual Congress 2011 - Multidrug-resistant tuberculosis
Year: 2011
Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country
Source: Eur Respir J 2013; 42: 1291-1301
Year: 2013
Management of multidrug-resistant tuberculosis and patients in retreatment
Source: Eur Respir J 2005; 25: 928-936
Year: 2005
Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016
Linezolid in the treatment of patients with MDR TB and XDR TB
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB)
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
The individual-tailored treatment regimens for multidrug-resistant tuberculosis
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Determinants of multidrug-resistant tuberculosis (MDR-TB) in Belarus
Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview
Year: 2012
Predictors of treatment outcome in multidrug-resistant tuberculosis
Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Year: 2011
TB drug resistance in high-incidence countries
Source: Eur Respir Mon 2012; 58: 95-110
Year: 2012
Facilities for treating multidrug-resistant tuberculosis (MDRTB) in Europe
Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology
Year: 2016
Treatment outcomes of extensively-drug resistant tuberculosis (XDR-TB) patients in 20 countries
Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment
Year: 2012
Treatment results in patients with XDR tuberculosis in Ukraine
Source: Eur Respir J 2007; 30: Suppl. 51, 272s
Year: 2007
Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia)
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration
Source: Eur Respir J 2016; 47: 686-688
Year: 2016
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB)
Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept